REGULATORY

12 Quasi-Original Drugs to Be Excluded from New Coverage Scheme

By Ken Yoshino April 23, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Twelve “quasi-original products” were not included in the list of medicines to be subject to a new health coverage rule slated to start this October, Jiho has learned. The list was disclosed by the Ministry of Health, Labor and Welfare…

To read the full story

MHLW Clarifies Criteria for “Medical Necessity” of LLPs before Elective Care Rollout
July 17, 2024
Japan Unveils 1,095 Off-Patent Branded Drugs Subject to New Coverage Rule
April 23, 2024

REGULATORY

LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
MHLW to Allow OTC Drugs to Match Prescription Doses under Specific Conditions
February 5, 2026
Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…